Philip G. Janicak, MD

Early interventions for psychosis

Author:: Morris B. Goldman, MD; Marko Mihailovic, MA, LCPC; Philip G. Janicak, MD

Despite considerable challenges, prevention and first-episode recovery programs may improve outcomes.

Options include OTC agents, anti-inflammatory/immune system therapies, and devices.

Some off-label agents show promise, but carry risks.

Recent developments have enhanced the benefits of this treatment.

Author:: Philip G. Janicak, MD; Vincet Sackett, MD; Karyn Kudrna, BSN, RN; Bradley Cutler, MD

The utility of TMS for treating depression continues to widen, as the technology is refined

Author:: Philip G. Janicak, MD; Sheila M. Dowd, PhD; Jeffrey T. Rado, MD; Mary Jane Welch, DNP, APRN, BC, CIP

Recent developments have revived interest in brain stimulation for difficult-to-treat patients

Risperidone’s metabolite behaves well but differently in once-daily delivery.

Surgical option for treatment-resistant depression

Despite early mixed results, magnetic stimulation of the prefrontal cortex is showing potential in major depression and other psychiatric...

Neuroleptics have played an important but controversial role in mood disorder treatment. Novel antipsychotic agents may represent a significant...